Dana-Farber

@DanaFarber

Dana-Farber Cancer Institute - a leading center for expert, compassionate cancer care and advanced research. Appts: 877-442-3324 | dana-farber.org

Boston, Massachusetts

dana-farber.org/social-media-p…

Joined June 2008

Pinned
Dana-Farber
@DanaFarber
Jun 2
A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic
00:00
Dana-Farber
@DanaFarber
8h
T cells need instructions from dendritic cells to find and attack cancer. But tumors can prevent these important immune cells from doing their job. Our researchers found that blocking an enzyme called CARM1 helped “wake up” dendritic cells and improve the activity of a cancer
blog.dana-farber.org
Dana-Farber Research Awakens Dendritic Cells Against Cancer
Dana-Farber researchers found that inhibiting CARM1 may awaken dendritic cells, strengthen T-cell activity, and improve cancer vaccine effectiveness.
Dana-Farber
@DanaFarber
Aug 18
Let’s just say the future’s looking good! 💙 We’re in awe of the genuine support, inspiring stories, and empowering motivation shared during this year’s @WEEI/@NESN @TheJimmyFund Radio-Telethon. We’re looking forward to putting this support to good use to advance the future of
00:00
Dana-Farber
@DanaFarber
Aug 15
Following a phase 3 clinical trial co-led by @OncoBellmunt, an @FDA-approved blood test can now determine which patients are at high risk of recurrence of muscle invasive bladder cancer and may benefit from additional treatment with the immunotherapy atezolizumab. Learn more ⬇️
FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber...
From blog.dana-farber.org
Dana-Farber
@DanaFarber
Aug 14
The U.S. Food and Drug Administration (FDA) has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma — the first approved CELMoD agent for this disease. Learn how our researchers helped advance iberdomide